Abstract
BackgroundThe IL6-antibody tolicizumab (TCZ) leads to a rapid improvement of the clinical course in patients with rheumatoid arthritis (RA) as assessed by the DAS28 score.4 However, in MR and ultrasound...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
